CRO/Sponsor

Today's sponsors are waking up to the fact that changes made between phases can positively impact R&D.

Peek into a future where drugs are approved faster and R&D is less costly thanks to technology.

Performance and noncompliance clauses change the partnership between sponsor and vendor.

Readers respond to the NEJM article mentioned in November's From the Editor

Strategies for labs to support global trials and meet the needs of sponsors worldwide.

A look at ECG evaluation for drug-related alterations in repolarization and Torsade de Pointes.

To select the right CRO as an imaging partner, sponsors must first be aware of what to look for.

With globalization of trials comes the difficulties of biologic sample logistics. Enter the centralized/decentralized laboratory model.

How imaging CROs minimize data variability in multisite studies and create the necessary consistency.

Tracking the life cycle of a drug is a complex process that early planning and IVR technology can help ease.

HemoBioTech Engages CRO to Facilitate Clinical Study in India of its Human Blood Substitute, HemoTech

New alternatives for e-clinical and data management. As EDC becomes more widely used in clinical trials, sponsors are not limited to one option but rather can choose different routes to optimize EDC efficiency.

EDC is being embraced by both continents, where its efficiency is welcomed despite a few kinks.

Emerging technologies are moving the industry closer to true IT solutions harmonization.

EDC is being embraced by both continents, where its efficiency is welcomed despite a few kinks.

A new study from Tufts highlights employee and fiscal growth in the industry from 2002 to 2005.

After parting ways in the late 90s, academic medical centers are revisiting industry-sponsored clinical trials.

Business needs and the processes built to support them are the driving force behind sound technological decisions.

Launched in 2003, the LCN Project calls for more studies and an improved trial infrastructure.

With its vast pool of patients and well-trained, English-speaking investigators, what exists to take advantage of in this research-rich country is clear. What needs to be given back, however, is not so clear. Despite the uncertainty, one thing seems evident: Responsibility is key to giving back.

While not a panacea, pharmacogenomics is still a valuable trial tool that can make the recruitment process more efficient and eliminate the high costs associated with late-stage product failure.

In this Web-based strategy, suppliers bid "down" prices for the privilege to sell their products and services. Is big pharma sold?

Generalizing fastest drug development strategies and practices.